USE, EFFECTIVENESS AND SAFETY OF IVABRADINE IN PEDIATRIC PATIENTS

Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

BACKGROUND
Ivabradine is authorized for the treatment of coronary artery disease and chronic heart failure with systolic dysfunction in adult patients, but there is little information on its efficacy and safety in pediatric population.

PURPOSE
To assess the use, effectiveness and safety of ivabradine in pediatric patients.

MATERIALS AND METHODS

RESULTS

PATIENTS’ CHARACTERISTICS

<table>
<thead>
<tr>
<th>N</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication: Inappropriate sinus tachycardia</td>
<td>4 (100%)</td>
</tr>
<tr>
<td>Median age (years)</td>
<td>5.6 (1.1 – 15.5)</td>
</tr>
<tr>
<td>Median starting dose (mg/kg)</td>
<td>0.08 mg/kg/12h</td>
</tr>
</tbody>
</table>

Dose decreased to a half in one patient due to QT prolongation
Normalisation after dose adjustment

SAFETY

Effectiveness assessment:
HEART RATE < 130 bpm

Safety assessment:
ADVERSE EVENTS

Effect of ivabradine on heart rate (HR)

CONCLUSIONS
Ivabradine seemed to be an effective and safe treatment for inappropriate sinus tachycardia in most of our pediatric patients. Nonetheless, more studies are required to confirm these results.

iratxe.marquinez@salud.madrid.org

Barcelona, 26-28 March 2014